CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,231 enrolled
Drug / intervention
semaglutide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01930188
NCT01930188Phase 3Completed
CompareCT.gov

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)

Novo Nordisk A/S·interventional·Posted Aug 28, 2013·Updated Jun 13, 2019

In Brief

A Phase 3 clinical trial evaluating semaglutide, sitagliptin, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 1,231 participants across 141 sites in 18 countries.

Detailed Summary

This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD (thiazolidinedione) in subjects with type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Bulgaria, Czechia, Hong Kong, Hungary, India, Japan, Mexico, Norway, Portugal, Romania, Russia, South Africa, Spain, Sweden, Thailand, Turkey (Türkiye), Ukraine
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 28, 2013
Enrollment StartDec 2, 2013
Primary CompletionOct 12, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.8 years ago

Interventions

semaglutidedrug

For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.

sitagliptindrug

Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.

placebodrug

Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.

placebodrug

For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.